New drug extends lung cancer survival 22 percent, UC Davis Cancer Center researchers report

June 03, 2006

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to final results from a national phase II trial. Results of the Southwest Oncology Group study, led by UC Davis Cancer Center researchers, were reported today at the annual meeting of the American Society of Clinical Oncology in Atlanta.

In the study, patients taking bortezomib plus gemcitabine and carboplatin had a median survival of 11 months, reported Angela Davies, an assistant professor of hematology and oncology at UC Davis Cancer Center and lead author of the study. In comparison, 9 months is the longest median survival seen in past SWOG trials of platinum-based chemotherapy treatments for advanced non-small cell lung cancer.

"These survival results are among the best ever reported in patients with NSCLC," Davies said. "We look forward to further study of bortezomib in combination with chemotherapy as treatment for NSCLC in a larger, phase III trial." In t

he study, 114 newly diagnosed stage IV and selected stage IIIB patients received gemcitabine and carboplatin in combination with bortezomib. The median overall survival was 11 months; one-year survival was 46 percent, with a median five-month progression-free survival. Other key findings:The study was supported by grants from the National Cancer Institute.

The Southwest Oncology Group is one of the largest National Cancer Institute-supported cancer clinical trials cooperative groups in the United States, with a network of more than 5,000 physician-researchers at nearly 550 institutions. Its lung committee is chaired by David R. Gandara, professor of hematology and oncology and director of the Clinical Research Program at UC Davis Cancer Center.

Lung cancer is the leading cause of cancer death among both men and women in the United States. According to the American Cancer Society, an estimated 174,470 people will be diagnosed with lung cancer this year, and 162,460 will die from it. Non-small cell lung cancer accounts for about 80 percent of lung cancer cases.

Bortezomib, sold under the trade name Velcade, is a small-molecule proteasome inhibitor originally approved as a treatment for multiple myeloma. It was developed by Millennium Pharmaceuticals, Inc., based in Cambridge, Mass.
-end-
UC Davis Cancer Center is the nation's 61st National Cancer Institute-designated center, serving a region of more than 6 million people in inland Northern California and California's Central Valley. More than 100 adult and 50 pediatric cancer clinical trials are under way at UC Davis Cancer Center at any given time.

University of California - Davis Health System

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.